DUBLIN--(BUSINESS WIRE)--The "Recombinant DNA Technology Market Analysis by Product (Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals), by Component, by Application, by End-use and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.
The global recombinant DNA technology market is expected to reach USD 844.6 billion by 2025.
Success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA (rDNA) technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.
Widespread successful application of this technique in veterinary product development, genetically modified crop development, bio pesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period.
Use of Genetically Modified (GM) products, such as GM animals, developed using rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess the GM products safety in context to its impact on human health and environment.
In addition, there is rising need to improve the recombinant proteins' production capacity by several folds, owing to increase in demand for effective therapeutics for disease treatment. The aforementioned fact pronounces the technological advances in this sector thus driving growth.
As per Monsanto and other proponents of GM crops, genetic engineering is one of the fastest and widely adopted agricultural innovations over the past few years. This, in turn, is expected bolster the adoption of rDNA technology for non-traditional applications.
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
Chapter 4 Product Estimates & Trend Analysis
Chapter 5 Component Estimates & Trend Analysis
Chapter 6 Application Estimates & Trend Analysis
Chapter 7 End-use Estimates & Trend Analysis
Chapter 8 Regional Estimates & Trend Analysis, by Product, Component, Application, & End-use
Chapter 9 Competitive Landscape
- Monsanto Company
- F. Hoffmann-La Roche Ltd
- Biogen
- Amgen Inc
- Novartis AG
- Eli Lilly and Company
- GenScript
- Pfizer Inc.
- Novo Nordisk A/S
- Sanofi
- Merck KGaA
- Profacgen
- Biocon
- GlaxoSmithKline plc.
- Cibus
- Horizon Discovery Group plc
- New England Biolabs
For more information about this report visit https://www.researchandmarkets.com/research/kv278v/recombinant_dna
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
